Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

References

• Janssen US. FDA approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s first cell therapy, a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma [updated 2022 Feb 28; 2022 Mar 1]. Available from: https://www.janssen.com/us-fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-bcma-directed-car-t
   Google Scholar
• Bristol Myers Squibb. U.S. Food and Drug Administration approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma; 2021 [updated 2021 Mar 26; 2021 May 14]. Available from: https://news.bms.com/news/corporate-financial/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-and-bluebird-bios-Abecma-idecabtagene-vicleucel-the-First-Anti-BCMA-CAR-T-Cell-Therapy-for-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx
   Google Scholar
• EMA. First cell-based gene therapy to treat adult patients with multiple myeloma [updated 2021 Jun 25; 2022 Jul 19]. Available from: https://www.ema.europa.eu/en/news/first-cell-based-gene-therapy-treat-adult-patients-multiple-myeloma
   Google Scholar
• Janssen. European Commission grants conditional approval of CARVYKTI® (ciltacabtagene autoleucel), Janssen’s first cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma [updated 2022 May 26; 2022 Jul 19]. Available from: https://www.jnj.com/european-commission-grants-conditional-approval-of-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma
   Google Scholar
• ClinicalTrials.gov. A study of JNJ-68284528, a chimeric antigen receptor T cell (CAR-T) therapy directed against B-cell maturation antigen (BCMA) in participants with relapsed or refractory multiple myeloma (CARTITUDE-1) [updated 2020 Dec 31; 2021 May 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03548207?term=NCT03548207&draw=2&rank=1
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety study of bb2121 in subjects with relapsed and refractory multiple myeloma (KarMMa) [updated 2020 Jun 16; 2021 May 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03361748?term=NCT03361748&draw=2&rank=1
   Google Scholar
• Martin T, Usmani SZ, Schecter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37(10):1779–1788.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Anderson LD, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J Clin Oncol. 2021;39(15_suppl):8016–8016.
   Web of Science ®Google Scholar
• Anderson LD, Shah N, Jagannath S, et al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin Lymphoma Myeloma Leuk. 2021;21:S17–S18.
   Web of Science ®Google Scholar
• Oriol A, San-Miguel J, Kansagra A, et al. Idecabtagene vicleucel (ide-cel, BB2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results. Hemasphere. 2021;5(S2):476.
   Google Scholar
• EMA. Assessment report: ABEMCA. Amsterdam, The Netherlands: European Medicines Agency; 2021. Available from: https://www.ema.europa.eu/en/documents/assessment-report/abecma-epar-public-assessment-report_en.pdf
   Google Scholar
• Lin X. US FDA statistical review – ABECMA; 2020 [updated 2021 May 18; 2021 May 28]. Available from: https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel
   Google Scholar
• Celgene Corporation. ABECMA (idecabtagene vicleucel) [package insert]. Summit (NJ): US Food and Drug Administration; 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel
   Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• SAS Institute Inc. SAS/STAT®14.3 user’s guide: the PHREG procedure. Cary (NC): SAS Institute Inc; 2017.
   Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Phillippo DA, Dias S, Palmer S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. Appendix D: worked example of MAIC and STC [updated 2016 Dec; 2021 May 14]. Available from: http://nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf
   Google Scholar
• Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–526.
   Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567.
   PubMed Web of Science ®Google Scholar
• FDA.gov. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma [updated 2020 Aug 6; 2021 May 31]. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma
   Google Scholar
• Karyopharm Therapeutics Inc. Karyopharm announces FDA approval of XPOVIO™ (selinexor) for the treatment of patients with relapsed or refractory multiple myeloma [updated 2019 Jul 3; 2021 Jun 2]. Available from: https://investors.karyopharm.com/2019-07-03-Karyopharm-Announces-FDA-Approval-of-XPOVIO-TM-selinexor-for-the-Treatment-of-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma
   Google Scholar
• Oncopeptides. FDA approves oncopeptides’ PEPAXTO® (melphalan flufenamide) for patients with relapsed or refractory multiple myeloma [updated 2021 Feb 26; 2021 Jun 2]. Available from: https://news.cision.com/oncopeptides-ab/r/fda-approves-oncopeptides–pepaxto––melphalan-flufenamide–for-patients-with-relapsed-or-refractor,c.3296082
   Google Scholar
• GlaxoSmithKline. FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma [updated 2020 Aug 6; 2021 Jun 2]. Available from: https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.
   PubMed Web of Science ®Google Scholar
• Saluja R, Cheng S, Santos KA, et al. Estimating hazard ratios from published Kaplan‐Meier survival curves: a methods validation study. Res Syn Meth. 2019;10(3):465–475.
   PubMed Web of Science ®Google Scholar
• Latimer N. NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data [updated 2013 Mar; 2021 Jun 4]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf
   Google Scholar